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A low frequency of Helicobacter pylori in the gastric mucosa of patients with alkaline gastritis has been reported. At the same
time, it can be noted that the growth of bacteria can be inhibited by bile acids. We studied 40 patients with chronic gastritis related
to Helicobacter pylori in order to determine the effect of ursodeoxycholic acid on this infection. Diagnoses of the infection and the
inflammatory process were obtained by histologic study of gastric biopsies collected during endoscopy. Two groups were studied:
group I received ursodeoxycholic acid - 300 mg/day, and group II received the placebo, twice a day, both for 28 days. The colonization
by Helicobacter pylori and the intensity of the mononuclear and polymorphonuclear inflammatory infiltrate were determined before
(time 1) and after (time 2) treatment. Ursodeoxycholic acid had no effect on the Helicobacter pylori infection. A significant reduction
in the intensity of the mononuclear inflammatory infiltrate of the gastric antrum mucosa was observed in patients from group I,
when we compared not only times 1 and 2 but also groups I and II. However, this was not the case with the body mucosa. We
concluded that ursodeoxycholic acid had no action on the colonization by Helicobacter pylori or on the polymorphonuclear
inflammatory infiltrate, but it caused a significant reduction in the intensity of the mononuclear inflammatory infiltrate of the gastric
antrum.
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Helicobacter pylori (Hp) coloniza-
tion has been reported to be infrequent
in gastritis secondary to duodeno-
gastric reflux (DGR)1, 2.
Bile acids (BA) are an important
part of DGR, and it has been consid-
ered that they may damage the gastric
mucosal barrier and also reduce local
bicarbonate secretion in patients with
abundant reflux, as is the case with
gastrectomized patients2. Conse-
quently, it would be easier for the hy-
drogen ion to diffuse towards the mu-
cosa, leading to a fall in pH level at the
cell surface, which would make the en-
vironment unfavorable for Hp2, 3. It has
been demonstrated in vitro that BA4, 5
have an inhibitory effect on Hp growth,
and studies have been reported6, 7 con-
cerning the use of BA in vivo in an at-
tempt to eradicate these bacteria.
The purpose of this study was to
determine the effect of ursodeoxy-
cholic acid (UDCA) on Hp coloniza-
tion of the gastric mucosa, as well as
to evaluate the occurrence of changes
in the mononuclear inflammatory infil-
trate (MNII) and in the polymorpho-
nuclear inflammatory infiltrate
(PMNII).
PATIENTS AND METHOD
The study was conducted on outpa-
tients with upper digestive complaints
who were referred for endoscopy of
the esophagus, stomach, and duode-
num and who had a histologic diagno-
sis of gastritis related to infection with
Hp.
During endoscopy, 6 biopsies were
obtained for anatomopathology and for
the detection of Hp. The first 3 biop-
sies were taken from the gastric antrum
at a 2.0 cm distance from the pylorus:
1 from the small curvature, 1 from the
anterior wall, and 1 from the posterior
wall. The other 3 biopsies were ob-
tained from the gastric body about 4.0
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cm above the incision: 1 from the large
curvature, 1 from the anterior wall, and
1 from the posterior wall.
The fragments were fixed in 10%
formalin and sent to the Department of
Pathological Anatomy. The slides were
stained by 2 methods: 1) the modified
Giemsa method for the detection and
quantification of Hp infection; and 2)
by the hematoxylin-eosin method for
histology with diagnosis and classifica-
tion of gastritis according to the crite-
ria of the Sydney System Classifica-
tion8. Only the histological results were
considered for the diagnosis of gastri-
tis, presence of Hp, and for inclusion
in the protocol. A semiquantitative cri-
terion based on counts of bacterial
numbers per microscopic field was
used to determine the intensity of in-
fection. The results were scored as fol-
lows: (+) up to 10 bacteria, (++) 11 to
30 bacteria, and (+++) countless bac-
teria in 1 or more foveolae or on the
cell surface.
The same professionals performed,
respectively, the endoscopic examina-
tion and the histopathological study for
the diagnosis of gastritis and the detec-
tion of Hp. The pathologist was un-
aware of the endoscopy results.
The patients included in the proto-
col were divided at random into 2
groups on a double-blind basis, with
the following order of entry:
GROUP I: Patients who received
UDCA, 300 mg/day/28 days taken in
2 daily doses, one at 9:00 a.m. and the
other at 4:00 p.m.
GROUP II: Patients who received a
placebo administered as for Group I.
On the first visit (time 1), medica-
tion was prescribed and all patients
were advised as to the possible occur-
rence of side effects. A second upper
digestive endoscopy was performed at
the end of their treatment (time 2) so
as to collect material for Hp detection,
followed by a new histological study.
We adopted a score system in or-
der to define, in an increasing order of
severity, the Hp colonization density
(HpD) and the intensity of MNII and
PMNII. We attributed scores 0, 1, 2,
and 3 respectively to grades 0, +, ++,
+++, or to absent, mild, moderate, and
intense, depending on whether the vari-
ables were HpD or histology. Score
points were compared in terms of the
significance of their variation between
times 1 and 2 for HpD, chronic gastri-
tis, and activity of the inflammatory
process between groups I and II for all
variables.
In agreement with the Declaration
of Helsinki 9, upon admission to the
study, the patients were informed about
the study project in detail and they
gave written consent to participate.
Data were analyzed by nonparamet-
ric methods. The classifying variables
are presented in contingency tables con-
taining absolute and relative frequen-
cies. The proportions of these variables
in both groups were analyzed by the
Fisher exact test. The continuous vari-
ables are presented in tables containing
means and standard deviations. Both
groups were compared by using the
Wilcoxon rank sum test. Variation of
mean score for the histological variables
between times 1 and 2 was compared
within each group. The level of signifi-
cance was set at p=0.05.
RESULTS
We studied 53 patients, but only 44
completed treatment. We excluded 4
from these 44 because faulty data hin-
dered analysis.
Table 1 shows the 40 patients dis-
tributed by group, age, and sex. Group
I consisted of 23 patients: 9 males
(39.13%) and 14 females (60.87%),
mean age (yrs) 27.47. Group II con-
sisted of 17 patients: 9 males (52.94%)
and 8 females (47.06%), mean age
(yrs) 28.82.
An individual study of each patient
shows that the elimination of infection
by Hp at time 2 after the use of UDCA
happened only in 2 cases. It is interest-
ing to note that these patients also had
a reduced intensity of the inflammatory
infiltrate.
Table 2 compares the mean scores
for HpD, MNII, and PMNII in the an-
trum and gastric body at time 1 between
groups I and II. An analysis of the 2
tables shows that both groups were ho-
mogeneous in terms of age, sex, and
variables analyzed at time 1, except an-
trum MNII, whose mean score was sig-
nificantly higher in group I.
Variables were evaluated by the
score system in the antrum and body at
times 1 and 2 in both groups. In refer-
ence to HpD, no difference was ob-
served between times or between groups
in either type of mucosa (Table 3).
With respect to MNII, table 4 shows
that the chronic inflammatory process in
the antral mucosa was significantly re-
duced in intensity in group I - patients
who used UDCA - when times 1 and 2
were compared, with a score variation
of -0.48 (p < 0.001). In contrast, group
II presented a positive variation of 0.06
(p = 1.000). When both groups were
Table 1 - Patient distribution by sex and age per groups I (treated with
ursodeoxycholic acid) and II (control).
Group I Group II
Variable Male Female Male Female p
n % n % N % n %
Sex 9.00 39.13 14.00 60.87 9.00 52.94 8.00 47.06 0.385
Age 27.47 ± 6.16 28.82 ± 5.67 0.485
 ±: mean ± standard deviation
 p: probability level
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compared at the two different times, the
reduction in inflammatory infiltrate that
was observed in group I was significant
(p = 0.049). In contrast, no significant
differences were detected in the mucosa
of the body.
Concerning PMNII, table 5 shows
no significant variation between times
1 and 2 within the same group or be-
tween groups.
DISCUSSION
A low frequency of Hp coloniza-
tion has been reported in patients with
abundant DGR10 undergoing partial
gastrectomy as a treatment for peptic
ulcers. The absence of bacteria may be
related to high indices of alkaline gas-
tritis and to elevated concentrations of
BA in gastric content1, 2, 3, 11. In 1989,
O’connor et al.3 also observed that sur-
geries for the correction of DGR led to
recolonization of gastric mucosa by
Hp. The disappearance of the bacte-
rium may be attributed to modifica-
tions in the characteristics of the gas-
tric epithelium, but is primarily related
to a lesion of the gastric mucosal bar-
rier by constituents of refluxed bile,
which may expose Hp to the action of
bile and acid 2, 3, 11. Some investigators
have also reported an inhibitory action
of bile4, especially of BA 5, on Hp
growth in vitro. Therefore, the absence
of Hp in stomachs with persistent DGR
may be caused by its intolerance to
bile. Based on these observations, the
use of BA was suggested in an attempt
to eradicate Hp 5.
In another in vitro study, Nilius et
al. (1993) 12 observed that UDCA and
chenodeoxycholic acid can induce
some ultrastructural changes on the cell
wall of Hp, which confirmed the toxic
and bactericidal power of BA on these
bacteria. After these observations, in
vivo studies using BA were undertaken
6
 in an attempt to eradicate Hp, some
of them indicating a possible therapeu-
Table 3 - Variation in mean score for colonization by Helicobacter pylori between
times 1 and 2 in the antrum and body of groups I (treated with ursodeoxycholic
acid) and II (control).
Variable Group I Group II p**
 HpD antrum Mean ± SD -0.22 ± 1.44 0.00 ± 0.79 0.691
p* 0.562 1.000
 HpD body Mean ± SD -0.61 ± 1.50 -0.06 ± 0.97 0.276
p* 0.081 0.906
SD: standard deviation
p*: probability level - comparison at basal conditions
p**: probability level - comparison of variability between groups
HpD: Helicobacter pylori colonization density
Table 2 - Comparison of the mean scores for the variables between groups I (treated
with ursodeoxycholic acid) and II (control) in the basal condition.
Variable Group I Group II p
 HpD antrum 2.35 ± 0.78 2.35 ± 0.70 0.940
 HpD body 2.26 ± 0.92 2.06 ± 1.09 0.615
 MNII antrum 2.17 ± 0.65 1.59 ± 0.62 0.009
 MNII body 1.22 ± 0.80 0.94 ± 0.75 0.302
 PMNII antrum 1.30 ± 0.70 1.00 ± 0.61 0.216
 PMNII body 0.87 ± 0.81 0.76 ± 0.75 0.714
 ±: mean ± standard deviation
 p: probability level
 HpD: Helicobacter pylori colonization density
 MNII: mononuclear inflammatory infiltrate
 PMNII: polymorphonuclear inflammatory infiltrate
Table 4 - Variation in mean score for mononuclear inflammatory infiltrate between
times 1 and 2 in the antrum and corpus of groups I (treated with ursodeoxycholic
acid) and II (control).
Variable Group I Group II p**
 MNII antrum Mean ± SD -0.48 ± 0.51 0.06 ± 0.90 0.049
p* <0.001 1.000
 MNII body Mean ± SD -0.22 ± 0.95 0.12 ± 0.70 0.314
p* 0.255 0.726
SD: standard deviation
p*: descriptive probability level - comparisons at basal conditions
p**: descriptive probability level - comparison of the variation between groups
MNII mononuclear inflammatory infiltrate
Table 5 - Variation in mean score for the polymorphonuclear inflammatory infiltrate
between times 1 and 2 in the antrum and corpus of groups I (treated with
ursodeoxycholic acid) and II (control).
Variable Group I Group II p**
 PMNII antrum Mean ± SD -0.09 ± 0.79 0.06 ± 0.66 0.617
p* 0.794 1.000
 PMNII body Mean ± SD -0.22 ± 0.95 0.00 ± 0.50 0.472
p* 0.297 1.000
SD: standard deviation
p*: descriptive probability level - comparison at basal conditions
p**: descriptive probability level - comparison of the variation between groups
PMNII: polymorphonuclear inflammatory infiltrate .
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tic action of BA, a result that stimu-
lated further investigations 7.
In the present in vivo study, the in-
hibitory effect of UDCA on Hp growth
that was observed by some investiga-
tors in vitro 4, 5 was not confirmed. The
use of this specific bile acid neither led
to the eradication of Hp, nor did it al-
ter the HpD when compared to the pla-
cebo. A histological study of 2 patients
from group I showed that Hp had dis-
appeared at time 2 both in the antrum
and in the body. This fact was accom-
panied by a decrease in MNII and
PMNII intensity. In a study, Graham et
al.6 did not detect an effect of UDCA
on gastric colonization by Hp. Silva et
al. in a pilot study7, found no infection
by Hp in 1 out of 5 patients who used
UDCA 10 mg/kg/day/30 days. Graham
et al.6 used this bile acid for just 2 days
in only 2 patients, and they concluded
that BA appears to be ineffective in the
treatment of this infection, possibly
because of the low solubility of gly-
cine-conjugated BA, as is the case with
UDCA at low pH values, such as the
gastric pH values, which would inac-
tivate them.
UDCA may act on Hp and on gas-
tric mucosa by either a systemic or a
local route, the latter being more prob-
able. The local effect may occur at two
different times. The first one would be
when the acid passes through the stom-
ach soon after administration in its
non-conjugated form. Experimental
data reported by Hoshita et al.13
showed that ingested BA may remain
in the stomach for about 1 hour, with
levels rapidly decreasing thereafter.
The second time would be when con-
jugated UDCA reflows into the stom-
ach 14 as the major constituent of bile15.
The systemic route is probably of little
importance, since the serum levels of
UDCA may be low and transitory, and
the acid circulating is mostly bound to
albumin and lipoproteins 16.
The present observations about an
improvement in the inflammatory in-
filtrate at the antrum level along with
the disappearance of Hp in 2 patients
after the use of UDCA, may indicate
that this non-conjugated acid, when
passing through the stomach soon af-
ter administration, and then acting in its
conjugated form with eventual reflux
into the stomach, may have some ef-
fect on the infection.
Some other factors should be men-
tioned for their possible influence on
the present results: the dose that was
employed, which may not have
reached adequate levels for bacterial
inhibition, as well as the use of the
medication for a sufficient extent of
time. Mathai et al.5 determined a mini-
mum inhibitory concentration of more
than 0.2% for UDCA. In the present
series we did not detect significant
changes in the gastric epithelium that
are characteristic of alkaline gastritis.
Since UDCA is a BA that leads to a
low level of inhibition of Hp5, and has
a low level of damaging power to the
gastric mucus layer and epithelium 17,
the intragastric concentration that was
reached in the present study, and the
time of treatment may not have been
sufficient to lead to changes in the mu-
cosal barrier, or in the gastric epithe-
lium typical of alkaline gastritis—
changes such as those observed in pa-
tients with abundant DGR and incom-
patible with the presence of Hp 2, 3, 11.
With respect to the inflammatory
process in the gastric antrum, a signifi-
cant reduction of MNII intensity was
observed at this dosage level in patients
from group I compared to those from
group II when time 1 was compared
with time 2. This alteration did not re-
cur in the body. The fact that these
studied groups were not homogeneous
in terms of the intensity of this MNII
in the antrum does not invalidate this
observation, since the statistical
method that was used compared both
groups in terms of score variation
within each separate group. The nega-
tive variation in group I and the posi-
tive variation in group II were mean-
ingfully different, reflecting the signifi-
cant reduction in MNII intensity in the
antrum of the group treated with
UDCA when compared to the placebo
group. This decrease cannot be ex-
plained by inhibition of Hp infection,
since no inhibition occurred. Also, no
significant change in PMNII intensity
was observed. According to Genta et
al. 18 and other investigators19, the re-
duction of these cells may be the first
indicator of successful combat against
Hp, with a gradual reduction of MNII.
The following questions may then
be formulated: why did a reduction of
the mononuclear inflammatory process
occur without a corresponding action
against Hp? Is it likely that present re-
sults reflect some inhibitory power of
UDCA against Hp? It is possible that
UDCA acts on some of the pathogenic
mechanisms of Hp, inhibiting the bac-
terium, or even that Hp is not the only
factor that is responsible for the inflam-
matory process observed in these pa-
tients, and that the bile acid acted on
this other factor. It is known that
UDCA has some inhibitory power on
urease release by the bacteria, with a
consequent reduction of ammonia pro-
duction12. Urease and ammonia are
known to be pathogenic for the gastric
epithelium20. Hp can release chemotac-
tic proteins20, which may attract mono-
nuclear and polymorphonuclear cells,
which in turn release substances such
as interleukin-2, tumor necrosis factor
(TNF), and free radicals. It has been
demonstrated in vitro that BA21 and
UDCA22 inhibit TNF, and interleukin-
2 release by mononuclear cells. It is
possible that UDCA has a similar ac-
tion on Hp and on the mononuclear
and polymorphonuclear cells located in
the gastric mucosa, a fact that, allied to
some decrease in urease activity, may
explain the reduction in MNII observed
here.
UDCA has little damaging power
on the gastric mucosal barrier17. It is
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not cytotoxic to most cells at any con-
centration because it binds minimally
to the cell membrane, and its micelle
has a low ability to solubilize mem-
branes24. These observations, however,
may be another explanation for the re-
duction in intensity of MNII. Assum-
ing that the present patients had some
degree of DGR, the predominance of
UDCA in bile after its oral administra-
tion15 would represent one less aggres-
sive factor against the mucosa, leading
to a regression in the inflammatory in-
filtrate.
In the present series, UDCA treat-
ment of patients with Hp-induced
chronic gastritis was followed by a re-
duced intensity of these MNII that was
not related to infection of the gastric
mucosa by the bacteria, which was not
affected by this drug.
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SILVA JGN da e col. - O ácido
ursodeoxicólico não interfere na
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lori, in vivo. Rev. Hosp. Clín. Fac.
Med. S. Paulo 55(6):201-206,
2000.
Tem sido relatada uma baixa fre-
qüência da infecção pelo Helicobacter
pylori na mucosa gástrica de pacientes
portadores de gastrite alcalina. Ao mes-
mo tempo, foi observada inibição do
crescimento da bactéria, in vitro, pelos
ácidos biliares. Com o objetivo de ava-
liar o efeito do ácido ursodeoxicólico
sobre a colonização da mucosa gástri-
ca por este microorganismo foram es-
tudados 40 pacientes com gastrite crô-
nica relacionada ao Helicobacter
pylori. O diagnóstico da infecção e do
processo inflamatório foi realizado por
estudo histológico de biópsias gástricas
coletadas durante a endoscopia. Foram
estudados dois grupos: o grupo I rece-
beu ácido ursodeoxicólico – 300mg/
dia, e o grupo II placebo, duas vezes
por dia, por 28 dias. A colonização pela
bactéria e a intensidade do infiltrado
inflamatório mono e polimorfonuclear
foram quantificados antes (tempo 1) e
depois (tempo 2) do tratamento. O áci-
do ursodeoxicólico não teve efeito so-
bre a infecção pelo Helicobacter
pylori. Observou-se redução signifi-
cante na intensidade do infiltrado infla-
matório mononuclear na mucosa gás-
trica do antro nos pacientes do grupo
I, tanto na comparação entre os tempos
1 e 2, quanto na comparação entre os
dois grupos. Entretanto, isto não ocor-
reu na mucosa do corpo gástrico. Po-
demos concluir que o ácido ursodeoxi-
cólico não tem ação na colonização
pelo Helicobacter pylori ou na inten-
sidade do infiltrado inflamatório
polimorfonuclear, mas causou uma re-
dução significante na intensidade do
infiltrado inflamatório mononuclear na
mucosa do antro gástrico.
DESCRITORES: Helicobacter py-
lori. Gastrite. Bactéria. Ursode-
oxicólico. Endoscopia.
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